Stocktoria
ABBOTT LABORATORIES ABT
ABBOTT LABORATORIES financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.3B | $42.0B | $40.1B | $43.7B | $43.1B | $34.6B | $31.9B | $30.6B | $27.4B | $20.9B |
| R&D expense | $2.9B | $2.8B | $2.7B | $2.9B | $2.7B | $2.4B | $2.4B | $2.3B | $2.3B | — |
| SG&A expense | $12.3B | $11.7B | $10.9B | $11.2B | $11.3B | $9.7B | $9.8B | $9.7B | $9.2B | $6.7B |
| Operating income | $8.1B | $6.8B | $6.5B | $8.4B | $8.4B | $5.4B | $4.5B | $3.6B | $1.6B | $3.0B |
| Interest expense | — | — | $637.0M | $558.0M | $533.0M | $546.0M | $670.0M | $826.0M | $904.0M | $431.0M |
| Income tax | $1.9B | -$6.4B | $941.0M | $1.4B | $1.1B | $497.0M | $390.0M | $539.0M | $1.9B | $350.0M |
| Net income | $6.5B | $13.4B | $5.7B | $6.9B | $7.1B | $4.5B | $3.7B | $2.4B | $477.0M | $1.4B |
| EPS (diluted) | $3.72 | $7.64 | $3.26 | $3.91 | $3.94 | $2.50 | $2.06 | $1.33 | $0.27 | $0.94 |
| Operating cash flow | $9.6B | $8.6B | $7.3B | $9.6B | $10.5B | $7.9B | $6.1B | $6.3B | $5.6B | $3.2B |
| Free cash flow | $7.4B | $6.4B | $5.1B | $7.8B | $8.6B | $5.7B | $4.5B | $4.9B | $4.4B | $2.1B |
| Cash & equivalents | $8.5B | $7.6B | $6.9B | $9.9B | $9.8B | $6.8B | $3.9B | $3.8B | $9.4B | $18.6B |
| Inventory | $6.5B | $6.2B | $6.6B | $6.2B | $5.2B | $5.0B | $4.3B | $3.8B | $3.6B | $2.4B |
| Total assets | $86.7B | $81.4B | $73.2B | $74.4B | $75.2B | $72.5B | $67.9B | $67.2B | $76.2B | $52.7B |
| Shareholders' equity | $52.8B | $47.9B | $38.8B | $36.9B | $36.0B | $33.0B | $31.3B | $30.7B | $31.1B | $20.7B |
Growth · year-over-year · Revenue CAGR 8.7%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +5.7% | +4.6% | -8.1% | +1.3% | +24.5% | +8.5% | +4.3% | +11.6% | +31.3% | +2.2% |
| Net income growth | -51.3% | +134.2% | -17.5% | -2.0% | +57.3% | +21.9% | +55.7% | +396.4% | -65.9% | -68.3% |
| EPS growth | -51.3% | +134.4% | -16.6% | -0.8% | +57.6% | +21.4% | +54.9% | +392.6% | -71.3% | -67.8% |
| Free cash flow growth | +16.4% | +25.5% | -35.2% | -9.8% | +51.1% | +27.3% | -8.3% | +10.6% | +113.0% | +12.2% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.